secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0000950170-25-033071
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q4 net loss $35.8M; revenue down 90% YoY; heme relapse data positive
--------------------------------------------------------------------------

- Net loss $35.8M in Q4 vs $19.6M YoY; full-year net loss $127.5M vs $89.2M.
- Revenue $0.7M Q4 vs $7.2M YoY; full-year $2.8M vs $21.0M, due to Amgen collaboration timing.
- Cash, equivalents and marketable securities $290.1M; funding into Q1 2027.
- ASH heme trial: 2/26 (8%) relapsed vs 4/12 (33%) control; HR 0.30.
- IND cleared for MAGE-A4 TCR-T; closed $30M registered direct offering at 37% premium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017025033071/0000950170-25-033071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017025033071/tcrx-20250305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-033071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer